Table 1.
The associations of SNHG1 expression with clinical pathologic features in patients with bladder cancer.
| Characteristics | Number | SNHG1 expression | p # | |
|---|---|---|---|---|
| Low | High | |||
| Gender | 0.625 | |||
| Male | 17 | 9 | 8 | |
| Female | 9 | 5 | 4 | |
| Age | 0.508 | |||
| ≤50 | 11 | 5 | 6 | |
| >50 | 15 | 7 | 8 | |
| Tumor number | 0.436 | |||
| ≤3 | 16 | 7 | 9 | |
| >3 | 10 | 5 | 5 | |
| Histological grade | 0.817 | |||
| G1 | 10 | 5 | 5 | |
| G2 | 10 | 6 | 4 | |
| G3 | 6 | 3 | 3 | |
| T stage | 0.154 | |||
| Ta,T1 | 17 | 9 | 8 | |
| T2-T4 | 9 | 4 | 5 | |
| N status | 0.097 | |||
| N0 | 16 | 6 | 10 | |
| N1,N2 | 10 | 4 | 6 | |
| M status | 0.756 | |||
| M0 | 18 | 8 | 10 | |
| M1 | 8 | 3 | 5 | |
The median expression level of SNHG1 was used as the cutoff. Patients with bladder cancer were divided into SNHG1 “Low’’ group (whose expression was lower than the median) and “High’’ group (whose expression was higher than the median).
#Fisher’s exact test.